4Tissue Appoints New CEO with £7M Funding

GHENT, Belgium, Oct. 22, 2026 /CourierPR/ -- 4Tissue, a Belgian medtech company developing solutions for regenerative medicine, has announced a €7 million Series A financing round and the appointment of Stéphanie Dupont as Chief Executive Officer (CEO). The company is developing a bioresorbable, injectable hydrogel designed to support natural tissue regeneration, with applications in breast reconstruction and augmentation. The technology aims to provide a less invasive, patient-friendly alternative to existing techniques. The financing will support 4Tissue’s next phase of development, including its first-in-human (FIH) study, manufacturing scale-up, and further development of its technology platform for additional applications in regenerative medicine.

Stéphanie Dupont, who brings more than 15 years of experience advancing innovative technologies from development through commercialization, has been appointed as the new CEO. She has held leadership positions at Barco, miDiagnostics, Talis Biomedical, HP, and Bain & Company, leading international teams across product management, marketing, and R&D. She holds a PhD in Materials Science & Engineering from Stanford University.

The Series A financing provides 4Tissue with the resources to accelerate clinical development and further strengthen its position in regenerative medicine.